Skip to main content

Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer

*November 2020*

In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK are now established actionable drivers of oncogenesis, made evident by the availability of FDA-approved and guidelines-indicated therapies for each other these aberrations.

Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium, hosted by Phyisicians’ Education Resource, LLC (PERÒ). Read more.